Global Chronic Obstructive Pulmonary Disease Market, By Type (Chronic Bronchitis, Emphysema), Treatment Type (Drugs, Surgery, Oxygen Therapy), End User (Hospitals, Clinics, Homecare Settings, Others) - Industry Trends and Forecast to 2030.
Chronic Obstructive Pulmonary Disease Market Analysis and Size
The rise in the cases of COPD among populations across the globe is among the important factor expected to intensify the growth and demand of the chronic obstructive pulmonary disease market. In addition, the rise in the consumption of tobacco among the youth population and the increase in the awareness among the population about the use of the generic drug are also expected to contribute to the growth in the global market over the forecast period. Also, the rise in the expenditure on healthcare is providing facilities in developing countries for chronic obstructive pulmonary disease, and the rise in awareness among people across developing and underdeveloped are also likely to enhance the growth of the market. Furthermore, the increase in the R&D investment by the government and major players is also one of the significant factors expected to fuel the growth of the chronic obstructive pulmonary disease market.
Data Bridge Market Research analyzes that the global chronic obstructive pulmonary disease market which was USD 19.8 billion in 2022, would rocket up to USD 30.4 billion by 2030, and is expected to undergo a CAGR of 4.4% during the forecast period 2023 to 2030. This indicates the market value. “Chronic Bronchitis” dominates the type segment of the global chronic obstructive pulmonary disease market owing to the surge in the number of people suffering from chronic obstructive pulmonary disease. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Chronic Obstructive Pulmonary Disease Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Chronic Bronchitis, Emphysema), Treatment Type (Drugs, Surgery, Oxygen Therapy), End User (Hospitals, Clinics, Homecare Settings, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
AstraZeneca (UK), Boehringer Ingelheim International GmbH (Germany), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), CHIESI Farmaceutici SpA (Italy), Sunovion Pharmaceuticals Inc (US), Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V. (US), Orion Corporation (Finland), Merck & Co., Inc (US), Grifols, S.A. (Spain), Abbott (US), F. Hoffmann-La Roche Ltd (Switzerland), Vectura Group plc (UK), Pfizer Inc (US), Alkermes (Ireland), Almirall, S.A (Spain), Genentech, Inc (US), Biogen (US), and Astellas Pharma Inc. (Japan), among other.
|
|
Market Opportunities
|
|
Market Definition
Chronic Obstructive Pulmonary Disease (COPD) is a type of chronic inflammatory lung disease that causes difficulty in airflow from the lungs. Various symptoms of COPD consist of difficulty in breathing, production of mucus, cough and wheezing.
Global Chronic Obstructive Pulmonary Disease Market Dynamics
Drivers
Increasing Awareness and Diagnosis
As medical knowledge and awareness of chronic obstructive pulmonary disease continue to grow, there may be an increase in the diagnosis and recognition of the condition. This can lead to a higher demand for diagnostic tools, treatments, and research related to chronic obstructive pulmonary disease.
Rise in the Cases of Copd
A significant global health issue, chronic obstructive pulmonary disease (COPD), affects a lot of individuals. The need for COPD management is growing as the disease burden grows. Smoking tobacco may increase the risk of COPD. Adult smoking addiction has been on the rise all around the world. Workplace pollution and indoor air pollution are additional risk factors.
Opportunities
Development of innovative therapies and treatment approaches
Most COPD treatments focus on managing symptoms and slowing the progression of the disease. However, there is a significant need for new and innovative therapies that provides better outcomes for patients and improve their quality of life. In recent years, research and development have focused on new COPD treatments, including biologics, gene therapies, and other novel approaches. These therapies potentially address the underlying causes of COPD and provide patients with more effective and targeted treatment options.
Restraints/Challenges
High cost of treatment:
COPD is a chronic disease that often requires long-term care and specialized treatment, which is expensive. In addition, many COPD patients also have other comorbidities, which further increase healthcare costs. The cost of COPD treatment is a major barrier to access for many patients, particularly in developing countries with high healthcare costs and limited insurance coverage. This leads to underdiagnoses and under treatment of the disease, negatively impacting patient outcomes and quality of life.
Recent Developments
- In April 2022, GlaxoSmithKline Pharmaceuticals launched Trelegy Ellipta for Chronic Obstructive Pulmonary Disease (COPD) patients. Trelegy Ellipta is India's first once-daily single-inhaler triple therapy (SITT) for COPD patients.
- In Feb 2022, Teva announced FDA approval of ArmonAir Digihaler inhalation powder, an inhaled corticosteroid (ICS) delivered via Teva’s Digihaler™ device containing built-in sensors and connects to a companion mobile application that provides information on inhaler use to people with asthma.
Global Chronic Obstructive Pulmonary Disease Market Scope
The global chronic obstructive pulmonary disease market is segmented on the basis of type, treatment type and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Chronic Bronchitis
- Emphysema
Treatment Type
- Drugs
- Bronchodilator Monotherapy
- Short-Acting Beta2-Agonists (SABAS)
- Long-Acting Beta2-Agonists (LABAS)
- Anti-Cholinergic Agents
- Anti-Inflammatory Drugs
- Oral And Inhaled Corticosteroids
- Anti-Leukotrienes
- Surgery
- Lung Volume Reduction Surgery (LVRS)
- Lung Transplant, Bullectomy
- Others
- Oxygen Therapy
End User
- Hospitals
- Homecare Settings
- Clinics
- Others
Global Chronic Obstructive Pulmonary Disease Market Regional Analysis/Insights
The global chronic obstructive pulmonary disease market is analyzed, and market size insights and trends are provided by country, type, treatment type and end user, as referenced above.
The countries covered in the global chronic obstructive pulmonary disease market report are the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.
North America dominates the global chronic obstructive pulmonary disease market because of the strong base of healthcare facilities, the strong presence of major players in the market, increasing cases of COPD conditions and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, a large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global chronic obstructive pulmonary disease market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global chronic obstructive pulmonary disease market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the chronic obstructive pulmonary disease market. The data is available for the historic period 2015-2020.
Competitive Landscape and Global Chronic Obstructive Pulmonary Disease Market Share Analysis
The global chronic obstructive pulmonary disease market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global chronic obstructive pulmonary disease market are:
- AstraZeneca (UK)
- Boehringer Ingelheim International GmbH (Germany)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- CHIESI Farmaceutici SpA (Italy)
- Sunovion Pharmaceuticals Inc (US)
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V. (US)
- Orion Corporation (Finland)
- Merck & Co., Inc (US)
- Grifols, S.A. (Spain)
- Abbott (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Vectura Group plc (UK)
- Pfizer Inc (US)
- Alkermes (Ireland)
- Almirall, S.A (Spain)
- Genentech, Inc (US)
- Biogen (US)
- Astellas Pharma Inc. (Japan)
SKU-